Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

HPTN 083

A phase 2b/3 double-blind safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis in HIV-uninfected cisgender men and transgender women who have sex with men.1

HPTN 084

A phase 3 double-blind safety and efficacy study of long-acting, injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis in HIV-uninfected cisgender women.2

About the HIV Prevention Trials Network (HPTN)

microscope image

The HIV Prevention Trials Network (HPTN) is a worldwide, collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. The National Institutes of Health, the National Institute of Mental Health, and the National Institute on Drug Abuse co-fund the HPTN.3

microscope image

References:

  1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021; 385:595-608.
  2. Delany-Moretlwe S, Hughes J, Bock P, et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. J Int AIDS Soc. 2021;24: SUPPL 1 (8).
  3. HPTN. About the HPTN. Accessed October 25, 2021. https://www.hptn.org/about